Korea’s evolving regulatory landscape for cell & gene therapies

Jaeseung Lim has been in the field of stem cell and cell therapy since 2000 and founded Cellatoz Therapeutics, Inc. in Sep 2017 to develop RM therapy including musculoskeletal and neurological cell therapy. He used to be a Chief Science Officer (CSO) at CHA Biotech Co. Ltd. (CHA Biotech). Under his leadership and driven by a commitment to R&D investment, CHA Biotech has developed one of the largest pipelines of regenerative medicine in the industry. Prior to serving as CSO of CHA Biotech, Dr Lim held a position in the field of pre-clinical research, clinical trials and product license advice in cell therapy as well as diagnostic kit and drug development. He also specialized in a development of cancer therapy using immune cells. When he was working as a research director with Innocell, Inc, the immunocellular therapeutics against liver cancer (Immunecell-LC^®) were approved in Korea. Dr Lim is an active member of the International Society of Cell and Gene Therapy (ISCT), Phacilitate meeting, Stem Cell and Regenerative Medicine Global Congress (SRGC), and Asian Cell Therapy Organization (ACTO). Dr Lim earned a bachelor’s and master’s degree in biochemistry from Seoul National University and doctoral degrees in biochemistry and molecular biology at University of Leeds in England.

Please enter your email to access content Read now